Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up

Parkinsonism and Related Disorders

Volumn 20, Issue 6, 2014, Pages 651-654

  Cossu, Giovanni ^a   Abbruzzese, Giovanni ^b   Matta, Gildo ^a   Murgia, Daniela ^a   Melis, Maurizio ^a   Ricchi, Valeria ^a   Galanello, Renzo ^c   Barella, Susanna ^c   Origa, Raffaella ^c   Balocco, Manuela ^d   Pelosin, Elisa ^b   Marchese, Roberta ^b   Ruffinengo, Uberto ^d   Forni, Gian Luca ^d  

^a BROTZU HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d GALLIERA HOSPITAL   (Italy)

Author keywords

Deferiprone; Iron; Magnetic resonance imaging; NBIA; PKAN

Indexed keywords

DEFERIPRONE; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOBUS PALLIDUS; HEMATOLOGIC DISEASE; HUMAN; IRON BRAIN LEVEL; IRON OVERLOAD; LONG TERM CARE; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; TREATMENT DURATION; YOUNG ADULT; IRON METABOLISM DISORDERS; LONGITUDINAL STUDY; NEUROAXONAL DYSTROPHIES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; SEVERITY OF ILLNESS INDEX;

ADULT; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON METABOLISM DISORDERS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROAXONAL DYSTROPHIES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PYRIDONES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84900024340     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.03.002     Document Type: Article

References (10)

1. Fredenburg A.M., Sethi R.K., Allen D.D., Yokel R.A. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 1996, 108(3):191-199.
2. Gregory A., Polster B.J., Hayflick S.J. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009, 46(2):73-80.
3. Schneider S.A., Dusek P., Hardy J., Westenberger A., Jankovic J., Bhatia K.P. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol 2013 Jan, 11(1):59-79.
4. Ferrochelating treatment in patients affected by neurodegeneration with brain iron accumulation (NBIA). http://clinicaltrials.gov/show/NCT00907283.
5. Abbruzzese G., Cossu G., Balocco M., Marchese R., Murgia D., Melis M., et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011 Nov, 96(11):1708-1711.
6. Zorzi G., Zibordi F., Chiapparini L., Bertini E., Russo L., Piga A., et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 2011 Aug 1, 26(9):1756-1759.
7. Forni G.L., Balocco M., Cremonesi L., Abbruzzese G., Parodi R.C., Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008 Apr 30, 23(6):904-907.
8. Kwiatkowski A., Ryckewaert G., Jissendi Tchofo P., Moreau C., Villaume I., Chinnery P.F., et al. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord 2012 Jan, 18(1):110-112.
9. Pratini N.R., Sweeters N., Vichinsky E., Neufeld J.A. Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen. Am J Phys Med Rehabil 2013 Aug, 92(8):728-733.
10. Vilchez-Abreu C., Roa-Sanchez P., Fermin-Delgado R., Speckter H., Perez-Then E., Oviedo J., et al. "The "eye-of-the-tiger" sign in magnetic resonance: age-related changes. An Radiol México 2013, 12(3):189-196.